The Motley Fool
20 Jun 2026, 06:00 UTC · 2h ago
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up.
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
20 Jun 2026, 06:00 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Vertex Pharmaceuticals has received FDA approval for Journavx, the first oral non-opioid pain signal inhibitor for moderate-to-severe acute pain. — First-mover advantage in a high-demand, non-opioid market provides a significant new revenue stream and diversification from CF drugs.
+0.60Eli Lilly is aggressively entering the non-opioid chronic pain market through the acquisitions of SiteOne Therapeutics and 4E Therapeutics. — Lilly is leveraging its capital to build a competitive pipeline in a new therapeutic area, though its assets are still in earlier stages than Vertex's.
+0.40Vertex is developing VX-993, currently in phase 2 studies for diabetic peripheral neuropathy (DPN). — Positive phase 2 results would expand Vertex's addressable market beyond acute pain into chronic neuropathy.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
Company leads the anti-obesity market and is aggressively diversifying into the non-opioid pain space through strategic acquisitions.
Company has a monopoly in CF and has made significant strides in non-opioid pain treatments with the approval of Journavx.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
1h ago
